Our study also has limitations; first and most important, we do not have clinical follow-up data after blood collection, and hence we cannot finally prove that patients developing adequate levels of IgG antibodies against the S1 protein but inadequate levels of neutralizing SARS-CoV-2 virus antibodies are at higher risk for infection and adverse clinical outcome. Here, PSMD1 is linked to infection.